Chemotherapy versus chemotherapy plus immune checkpoint inhibitors for the first‐line treatment of unresectable thymic carcinoma: A multicenter retrospective study
International Journal of Cancer · 2024
DOI: 10.1002/ijc.34948 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Baishen Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Guangdong Provincial Clinical Research Center for Cancer, Guan…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Thymus Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Thymoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Thymic carcinoma (TC) is a rare malignant tumor with a poor prognosis, and there is currently limited data on the use of immunotherapy in patients with unresectable TC. In this study, data of patients with unresectable TC diagnosed from January 2017 were retrospectively collected from multiple centers. Treatment response, progression‐free survival (PFS), overall survival (OS), survival‐independent prognostic factor, and adverse events (AEs) were further analyzed. As a result, a total of 93 patients with unresectable TC were enrolled, of which 54 received first‐line chemotherapy, and 39 received chemotherapy plus immune checkpoint inhibitors (ICIs). The objective response rate was 50% (27/54) in the chemotherapy group and 76.9% (30/39) in the chemotherapy plus ICIs group. The chemotherapy plus ICIs group achieved significant median PFS benefit (8.8 vs. 34.9 months, p < .001) and median OS benefit (41.8 months vs. not reached, p = .025). Multivariate analysis showed that ICIs and local therapy were independent prognostic factors for PFS. In addition, 17 patients developed immune‐related AEs (IRAEs), of which 15 (38.5%) had Grade 1 or 2 IRAEs and 2 (5.1%) had Grade 3 IRAEs in the chemotherapy plus ICIs group. In conclusion, the efficacy of chemotherapy plus ICIs is superior to chemotherapy, and the adverse effects are manageable in patients with unresectable TC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
- Department of Thoracic Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China.
- Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Department of Medical Oncology, Sun Yat-Sen University Cancer Center; State Key Laboratory of Oncology in South China; Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
ORCID-Profile: Baishen Zhang, Hui Yu, Chao Cheng, Likun Chen
Zitieren
APA
Zhang, B., Liu, Y., Chen, Z., Chen, J., Yu, H., Li, M., Ma, S., Cheng, C., & Chen, L. (2024). Chemotherapy versus chemotherapy plus immune checkpoint inhibitors for the first‐line treatment of unresectable thymic carcinoma: A multicenter retrospective study. International Journal of Cancer. https://doi.org/10.1002/ijc.34948
Vancouver
Zhang B, Liu Y, Chen Z, Chen J, Yu H, Li M, et al. Chemotherapy versus chemotherapy plus immune checkpoint inhibitors for the first‐line treatment of unresectable thymic carcinoma: A multicenter retrospective study. International Journal of Cancer. 2024. doi:10.1002/ijc.34948
BibTeX
@article{Zhang2024,
author = {Zhang, Baishen and Liu, Yao and Chen, Zhiting and Chen, Jing and Yu, Hui and Li, Meichen and Ma, Shudong and Cheng, Chao and Chen, Likun},
title = {Chemotherapy versus chemotherapy plus immune checkpoint inhibitors for the first‐line treatment of unresectable thymic carcinoma: A multicenter retrospective study},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.34948}
}
EUVIMED